Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Comprehensive Genomic Testing Reveals Treatment Targets In 90% Of Advanced Solid Tumors

By LabMedica International staff writers
Posted on 31 Jul 2025

Patients with advanced solid tumors often face limited treatment options, in part because conventional testing methods fail to detect many of the genetic mutations that could guide targeted therapies. More...

Many significant alterations occur at low levels and may be missed by simpler diagnostics, leading to missed opportunities for personalized care. Additionally, standard DNA testing can overlook gene fusions—unusual genetic events that can drive cancer growth—leaving clinicians without crucial information to inform therapy planning. The need for comprehensive, sensitive, and inclusive molecular testing is critical in ensuring that subtle but therapeutically relevant mutations are identified. Now, a new study has revealed that over 90% of tumor samples contained genetic changes that could help guide treatment decisions, offering new hope for personalized cancer care.

The study, led by Exact Sciences (Madison, WI, USA), utilized the company’s OncoExTra assay to analyze over 10,000 advanced solid tumor samples. The research covered 31 types of cancers, including breast, prostate, colorectal, lung, and ovarian. The OncoExTra assay integrates both DNA and RNA sequencing to provide a full molecular profile of each tumor. This dual approach is particularly valuable in detecting gene fusions and other events that may not be apparent through DNA sequencing alone. According to the findings, published in Oncotarget, 29.2% of samples had biomarkers linked to on-label treatments, while 28.0% were associated with off-label therapies.

Additionally, 7.5% of samples contained gene fusions, reinforcing the importance of including RNA sequencing in molecular diagnostics, which helped identify high rates of gene fusions in prostate cancer and certain sarcomas. The results validate the assay’s ability to detect a wide range of clinically relevant genomic alterations, including rare or low-level mutations and fusion events. By identifying these genetic events, the test paves the way for precision therapies and improved patient outcomes. This advanced testing method reveals treatment opportunities even in advanced cancers, potentially guiding more personalized cancer care in real-world clinical settings.

Related Links:
Exact Sciences


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Electrolyte Analyzer
BKE-B
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.